COVID-19感染后肌钙蛋白升高的蛋白质组学见解
CISCO-19前瞻性多中心队列研究纳入267例住院PCR确诊COVID-19患者,在入组时和28-60天进行血浆蛋白质组学、心血管MRI和临床生物标志物评估。高敏肌钙蛋白-I在入组时仅轻度升高(中位数3 ng/L),平滑肌肌球蛋白轻链蛋白在随访时下调并与高敏肌钙蛋白-I正相关,提示肌钙蛋白升高可能反映系统性血管损伤而非心肌损伤。
要点
- 住院COVID-19患者高敏肌钙蛋白-I仅轻度升高,中位数3 ng/L(IQR 2-6)。
- 平滑肌肌球蛋白轻链蛋白随访时下调,与高敏肌钙蛋白-I正相关,但与心脏MRI指标无关。
- 肌钙蛋白升高可能反映系统性血管损伤,需重新解读病毒性疾病中的心脏生物标志物。
核心结论
- 肌钙蛋白升高(以COVID-19为例)可能反映系统性血管损伤,而非 overt 心肌损伤。
研究设计与样本
- CISCO-19(NCT04403607)为前瞻性、多中心队列研究,纳入267例住院PCR确诊COVID-19参与者,在入组时和28-60天进行多系统评估。
- 研究包括血浆蛋白质组学(SOMAscan V.4.1)、心血管MRI和临床生物标志物;211例有基线血浆蛋白质组数据,185例完成随访采样,155例有匹配的蛋白质组和影像数据(平均年龄55岁,SD 12;43%女性)。
主要发现
- 13.2%(21/159)的参与者被判定为高度可能心肌炎。
- 入组时高敏肌钙蛋白-I轻度升高(中位数3 ng/L;IQR 2-6;n=159)。
- 男性(n=90)中9.3%的高敏肌钙蛋白超过34 ng/L,女性(n=69)中4.5%超过16 ng/L。
- 随访时平滑肌肌球蛋白轻链蛋白下调(log2倍数变化-0.12至-0.6;所有调整后p<0.02),并与高敏肌钙蛋白-I正相关,但与N末端脑钠肽前体或心脏MRI指标无关(n=155)。
临床怎么用
- 在病毒性疾病中解读肌钙蛋白升高时,应考虑系统性血管损伤的可能,避免仅归因于心肌损伤。
- 未来治疗策略和生物医学研究可探索血管损伤的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Raised cardiac troponin-I is a common finding in patients hospitalised with acute viral infections, including but not limited to COVID-19. This often occurs in the absence of overt myocardial injury presenting a challenge for interpretation. The mechanisms underlying troponin elevation are uncertain. METHODS: The CISCO-19 (Cardiovascular Imaging in SARS-CoV-19) study (NCT04403607) is a prospective, multicentre cohort study, in which hospitalised PCR-confirmed COVID-19 participants (N=267) underwent multisystem evaluation at enrolment and at 28-60 days. The study incorporated plasma proteomics (SOMAscan V.4.1), cardiovascular MRI and clinical biomarkers. Of these, 211 had baseline plasma proteomic data and 185 completed follow-up sampling. Matched proteomic and imaging data were available for 155 participants (mean age: 55 years (SD 12); 43% female). RESULTS: A high likelihood of myocarditis was identified in 13.2% (N=21/159) of participants. High-sensitivity troponin-I was modestly elevated at enrolment (median 3 ng/L; IQR 2-6; n=159). Among males (n=90), 9.3% had a high-sensitivity troponin that exceeded 34 ng/L. Among females (n=69), 4.5% exceeded 16 ng/L. Smooth muscle myosin light chain proteins were downregulated at follow-up (log2 fold change -0.12 to -0.6; all adjusted p<0.02) and positively correlated with high-sensitivity troponin-I, but not N-terminal brain natriuretic peptide or cardiac MRI indices (n=155). CONCLUSIONS: Troponin elevation, exemplified here by COVID-19, could reflect systemic vascular injury. Recognising this mechanism may refine interpretation of cardiac biomarkers in viral illness and supports the investigation of vascular injury in future therapeutic strategies and biomedical studies.
引用
- Kamdar A, Ang DTY, Mangion K, et al. Proteomic insights into troponin elevation following COVID-19 infection. Heart. 2026. PMID: 41802850. doi:10.1136/heartjnl-2025-326786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。